Navigation Links
GenVec Presents Research on New Ad35 Adenovector at ARVO

d 85. New therapies to treat AMD have demonstrated benefit but these therapies must be injected every four to six weeks. GenVec believes its gene transfer approach may provide an effective and more convenient treatment for AMD.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company's product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec's lead product, TNFerade(TM) is currently in a pivotal Phase II/III study (PACT) in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease (FMD), respiratory syncytial virus (RSV), and seasonal and pandemic flu. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization,
'"/>




Page: 1 2 3

Related medicine technology :

1. GenVec Announces Update of Safety and Efficacy Data from Pivotal Phase II/III PACT Study of TNFerade at ASCO
2. GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti-Cancer Therapy
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: GenVec Presents Research New Adenovector ARVO
(Date:11/19/2009)..., , TAINAN, Taiwan, Nov. 19 /PRNewswi...of active pharmaceutical ingredients (APIs), annou...ent Compound Safety Certification from,SafeBridge(...inoPharm,s,competency and proficiency in the safe ...ts (APIs), and applies to specific laboratories an...
(Date:11/19/2009)..., , CAMBRIDGE, Mass., Nov. 19 /PRNewswire... small molecule microarray technology to find drug... it has raised $1M in seed financing led by incTAN...mplete its initial discovery campaign that will sc...With this investment, incTANK Ventures General Par...
(Date:11/19/2009)..., , NEWPORT NEWS, Va., Nov. 19 /PRNewswire/... Imaging (BSGI/MBI) has been recognized and endors...ght against breast cancer: The Society of Breast I... Both societies published articles supporting the ...echnology for the early detection of breast cancer...
Breaking Medicine Technology:ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 2Cambridge-based Ligon Discovery Raises $1M in Seed Funding 3Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 2Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 3Drinking Your Way to Health 3F Perhaps Not 59700 1Drinking Your Way to Health 3F Perhaps Not 59700 2Drinking Your Way to Health 3F Perhaps Not 59700 3A new understanding of why seizures occur with alcohol withdrawal 59697 1Post Traumatic Stress May Raise Death Risks 59693 1Post Traumatic Stress May Raise Death Risks 59693 2
... -Biologics License Application for Wrinkles/Nasol... Two Weeks- , , , EXTON, Pa., March 5 Isolagen(...top-line efficacy results from a Phase II/III clin...y(TM) for the treatment of moderate to severe acne...ts and was statistically significant, making this ...
... mTBI Accident , , Presentation at American Balan...eturning Vets , , PITTSBURGH, March 4 With recor... and Afghanistan with brain injuries, a case study...ics.com ) suggests that tests utilizing its I-Port... generate results that may indicate mild traumatic...
Other Medicine Technology:Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 2Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 3Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 4Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 5Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 6Neuro Kinetics: Research Suggests I-Portal(R) NOTC Data Shows Mild Traumatic Brain Injuries That Other Technologies Miss 2Neuro Kinetics: Research Suggests I-Portal(R) NOTC Data Shows Mild Traumatic Brain Injuries That Other Technologies Miss 3
(Date:11/22/2009)... HealthSmart, an innovative healthcare benefit...ccessfully completed a recapitalization with Silve...r lenders. Silver Point Capital, L.P. is a privat... This recapitalization allows the Company to cont...y. , , (PRWEB) November ...
(Date:11/21/2009)...N, Nov. 21 DNC Chairman...e Senate voted to begin full debate of health insu...w.newscom.com/cgi-bin/prnh/20080519/DNCLOGO ) ,...on the road to enacting health insurance reform. B...will now have an opportunity to debate the health ...
(Date:11/21/2009)... November 21, 2009 Test ...Test Test Test Test Test Test Test Test,Test Test ...Test Test Test,Test Test Test Test Test Test Test ... test More test More test More test More test More... test More test More test More,test More test , ,...
(Date:11/21/2009)... New Haven Dental Group merges their practice ... CT. , (PRWEB) November 2...f partners Dr. David Gibson, Dr. Dean Cloutier, Dr... merged their growing practice with that of esteem...ickman decided he wanted to retire from dentistry ...
(Date:11/20/2009)...NGTON, Nov. 20 The Unit... Senate to make essential changes its health refor...ortion funding and conscience protection on aborti...nd include strong provisions for adequate affordab...care bill an "enormous disappointment" that create...
Breaking Medicine News(10 mins):Health News:HealthSmart Completes Recapitalization to Support Continued Growth, Daniel D. Crowley Named Chairman 2Health News:Democratic National Committee Chairman Tim Kaine's Statement on the Senate's Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 2Health News:New Haven Dental Group Expands Their Vision 2Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2
...nd vitamin C reduced blood pressure back to normal...s a pilot study.// "Combinations of garlic a...ontrol of marginally high blood pressure," wrote a...al cell NO production, an effect that was shown to...
... herbal drug could be damaged by overplanting of t...orld Health Organization (WHO) said on Monday. ... be more carefully farmed to meet a growing global...r centuries. It is now widely regarded as the best...
... an eye each allegedly due to medical neglect afte...d the patients// were to blame because they had no...dministration had organised a cataract operation c...who belong to Boden, Gunduri, Khandapal and Latapa...
...on for clinical trials for many pharmaceutical gia...Squibb, GlaxoSmithkline, Eli Lilly are among those... Currently over 226 clinical trials approved...icipants at home, western drug companies are looki...
...'t cause the pain and bruising common with existin...eam in California. In a bid to confront the ... the pain and discomfort experienced by patients, ... drug delivery company StratGent Life Sciences. ...
...Wanganui hospital is reported to have practiced fo...ed sterilization// procedures. While talking o... that Dr. Hasil was having various problems in his...ures last year. The general failure rate in such p...
Other Medicine News:Health News:Garlic Plus Vitamin C may Reduce Blood Pressure 2Health News:Malaria-curing Herb Must Be Carefully Farmed - WHO 2Health News:India Fast Become Prime Location for Clinical Trials, but Vigilance Called for 2Health News:Micro-jets for Painless Needle-free Injections 2Health News:Micro-jets for Painless Needle-free Injections 3
SureStep AMPII/BZO300/COC/MDMA/MOP/THC
SureStep THC/COC/MAMPII
SureStep THC/COC
SureStep Barbiturates (BAR)
Medicine Products: